What changed from existing technology?
This study helps make it easier to understand and report results from high-speed lab tests that check how chemicals might harm people.
This is the first study to specifically curate and annotate HTS data for toxicological interpretation within a regulatory context.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
us, applying them to decisions about chemical effects remains a challenge. To overcome this challenge and help democratize HTS data, we curated and annot
Abstract ↗OpenAlex author affiliations: General Dynamics (Canada)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This curation workflow could help improve the consistency and reliability of toxicological assessments using HTS data in regulatory decision-making.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchEnhancing toxicological interpretation and reporting of in vitro high-throughput screening dataFrontiers in Toxicology · Published 2026-08-24 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.